WO2005097152A1 - 粘結性が改善されたウコン抽出物含有組成物 - Google Patents
粘結性が改善されたウコン抽出物含有組成物 Download PDFInfo
- Publication number
- WO2005097152A1 WO2005097152A1 PCT/JP2005/005175 JP2005005175W WO2005097152A1 WO 2005097152 A1 WO2005097152 A1 WO 2005097152A1 JP 2005005175 W JP2005005175 W JP 2005005175W WO 2005097152 A1 WO2005097152 A1 WO 2005097152A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- extract
- fatty acid
- lipophilic emulsifier
- weight
- mct
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
Definitions
- composition containing konkon extract with improved caking properties Composition containing konkon extract with improved caking properties
- the present invention relates to a composition containing a cocoon extract with improved caking properties, which facilitates the use of a cocoon extract having an effect of preventing or improving multiple 'risk' factor syndromes.
- Ginger which is classified into the genus Gingidae (spring gong: Curcuma aromatica, autumn gong:
- Curcuma longa is generally known as turmeric, one of the curry spices, and is widely used as food.
- traditional therapies such as Chinese herbal medicine, Indian aurveda, and Indonesian jams have long been known to have haemostatic, stomach, antibacterial and anti-inflammatory effects. It's being used. Attention has also been paid to the effects of turmeric and its major component, curcumin, which have antioxidant effects, bile secretion promoting effects (biliary effects), visceral (liver, visceral) function enhancing effects, carcinogenesis suppressing effects, lipid metabolism improving effects, and whitening.
- biliary effects bile secretion promoting effects
- visceral liver, visceral
- carcinogenesis suppressing effects lipid metabolism improving effects
- whitening Various physiological actions such as actions have been elucidated.
- konkon extract has an effect of preventing or improving the multiple risk factor syndrome such as visceral fat obesity, diabetes, hyperlipidemia and hypertension (International Publication No. 476 99 pamphlet), icon is an extremely
- the konkon extract ( ⁇ konoleoresin) is curcumin and curcumin derivatives
- Patent Document 1 WO 02/47699
- Patent Document 2 JP-A-9-111282
- Patent Document 3 JP 2001-86931A
- Patent Document 4 JP-A-2003-137799
- An object of the present invention relates to the use of a macaque extract having an extremely useful physiological action, and solves the problems of poor fluidity and adhesion to containers and the like by improving the above-mentioned undesirable properties.
- Another object of the present invention is to provide a composition containing a high concentration of corn extract, which is extremely difficult to handle as it is.
- the present inventors have conducted intensive studies and as a result, by mixing a cocoon extract with an edible oil / fat and / or a specific emulsifier, the caking property was remarkably improved, and the cocoon extract was improved The present inventors have found that a slurry having good fluidity can be obtained even if it is contained at a concentration, and have completed the present invention.
- a first aspect of the present invention is that a lipophilic emulsifier containing a corn extract in an amount of more than 40% by weight, and having a medium chain fatty acid triglyceride and Z or fat and / or HLB value of 8.5 or less.
- the present invention relates to a composition comprising a grape extract.
- a preferred embodiment relates to the composition described above, characterized by comprising a medium-chain fatty acid triglyceride and a lipophilic emulsifier having a Z or HLB value of 8.5 or less.
- the lipophilic emulsifier is a glycerin fatty acid ester, the composition containing a coconut extract described above, and further preferably, the lipophilic emulsifier is a polyglycerin fatty acid ester.
- the corn extract extract-containing composition particularly preferably the corn extract extract-containing composition described above, wherein the constituent fatty acids of the polyglycerin fatty acid ester are unsaturated fatty acids, and very preferably the lipophilic emulsifier is diglycerin monoester.
- the above-mentioned composition comprising a cocoon extract, which is an ester of oleic acid, and most preferably the effect of preventing or ameliorating multiple 'risk' factor syndrome. Extract-containing composition.
- a second aspect of the present invention relates to a capsule enclosing the above-described composition.
- a composition having a high viscosity and a low adherence to a container or the like can be provided despite containing a high concentration of a corn extract. Therefore, for example, it becomes easy to encapsulate the useful component of the cocoon in a soft capsule or the like at a high concentration.
- the composition of the present invention has a very useful physiological activity, it has a high viscosity, a caking property, a poor fluidity and often adheres to a container.
- a medium-concentrated triglyceride and / or fat and oil and a lipophilic emulsifier having a Z or HLB value of 8.5 or less with a high-concentration corn extract having a high concentration, the fluidity, adhesion and uniformity are excellent.
- the composition containing the cocoon extract of the present invention has an advantage that it has an effect of preventing or ameliorating multiple 'risk' factor syndromes because it contains a high concentration of the cocoon extract.
- a soft capsule containing a high-concentration cocoon extract can be used. It has the advantage that it can be easily manufactured.
- the cocoon extract-containing composition of the present invention is obtained by mixing a cocoon extract with an oil component, which improves fluidity, and / or a lipophilic emulsifier, which improves cohesion.
- the method for producing the icon extract of the present invention is not particularly limited, and it can be obtained by a conventionally known method, for example, a method of extracting the rhizome of the icon with warm ethanol. It is also possible to use commercially available Coneole Resin as it is.
- the iconic extract used in the present invention includes curcumin, curcumin derivatives (eg, demethoxycurcumin, bisdemethoxycurcumin, dihydrocurcumin, tetrahydrocurcumin, hexahydrocurcumin, dihydroxytetracurcumin, etc.) and pisaborane-type
- curcumin includes, for example, 1-bisabolene, ⁇ -curcumene, gingiberene, 1-sesquiferandrene, ar-turmerone, ⁇ -turmerone, and 3-turmerone.
- the medium-chain fatty acid triglyceride (hereinafter also referred to as MCT) used in the present invention is a triglyceride having a fatty acid residue having 6 to 10 carbon atoms as a constituent fatty acid residue.
- the fats and oils used in the present invention are edible fats and oils other than medium-chain fatty acid triglycerides, and are not particularly limited.
- vegetable oils such as corn oil, rapeseed oil, high cinnamon rape oil, soybean oil, olive oil, safflower oil, cottonseed oil, castor oil, rice bran oil, palm oil, palm kernel oil, etc., fish oil, beef tallow, lard, milk fat, egg yolk
- Animal oils such as oils, oils and fats which have been subjected to separation, hydrogenation, transesterification and the like using these as raw materials, or mixed oils thereof can be used.
- the lipophilic emulsifier used in the present invention is not particularly limited as long as it can be uniformly mixed with the cocoon extract or the cocoon extract and fats and oils, but the HLB value is preferably 8.5 or less, more preferably 3 or less. —8.5, more preferably 5-8.5. This is because it is preferable that the solvent used for extracting the cocoon be closer to the lipophilicity.
- the lipophilicity mentioned here means that it can be dissolved in fats and oils, and those that can be dissolved in MCT or general edible fats and oils are defined as lipophilic emulsifiers. When the HLB value exceeds 8.5, emulsifiers are separated from cocoon extract and oils and fats May be.
- the HLB value is generally a measure of the degree of hydrophilicity and lipophilicity of an emulsifier, and the smaller the value, the stronger the lipophilicity.
- the method for determining the HLB value is not particularly limited, but can be determined, for example, by the following formula (see Dani Gakushi Dictionary, Tokyo Kagaku Dojin, 1st edition, published on October 1, 1994).
- emulsifiers include glycerin fatty acid esters such as monoglycerin fatty acid ester, monoglycerin fatty acid organic acid ester, polyglycerin fatty acid ester, polyglycerin condensed ricinoleate ester, sorbitan fatty acid esters, polysorbates, Sugar fatty acid esters, propylene glycol fatty acid esters, lecithin and the like can be mentioned, and at least one of them can be used in combination.
- polyglycerin fatty acid esters and polyglycerin condensed ricinoleate are more preferable, since glycerin fatty acid esters are preferred because they can effectively improve the caking property.
- the caking property as referred to in the present invention means a balance between fluidity, adhesion to a container, and uniformity of each component of a composition containing a cocoon extract. The better the above three properties, the better the caking property. Also means good
- Examples of the polyglycerin fatty acid ester and the polyglycerin condensed ricinoleate include an average degree of polymerization of polyglycerin of 2 to 10. Further, examples of the polyglycerin fatty acid ester include those in which the constituent fatty acid is a fatty acid having 6 to 22 carbon atoms. Among them, the constituent fatty acid is preferably an unsaturated fatty acid.
- diglycerin monooleate Tetraglycerin pentaoleate, hexaglycerin pentaoleate, pentaglycerin trioleate, decaglycerin pentaoleate, decaglycerin decaoleate, decaglycerin depot oleate, etc.
- diglycerin monooleates Tetraglycerin pentaoleate, hexaglycerin pentaoleate, pentaglycerin trioleate, decaglycerin pentaoleate, decaglycerin decaoleate, decaglycerin depot oleate, etc.
- diglycerin monooleates referred and more preferred are diglycerin monooleates.
- the lipophilic emulsifier having an MCT, fat or HLB value of S8.5 or less at least one of them can be used as long as it can be uniformly mixed with a cocoon extract. ⁇ As the content of corn extract increases, lipophilic emulsifiers with MCT and Z or HLB values of 8.5 or less are preferred. A mixture of lipophilic emulsifiers having an MCT and HLB value of 8.5 or less is more preferred. MCT is known to have a lower viscosity than general fats and oils and an effect of suppressing body fat.It is a uniform and fine slurry compared to general fats and oils, and has a large effect of improving fluidity and uniformity. A lipophilic emulsifier having an HLB value of 8.5 or less has a large effect of improving adhesion.
- the contents of the cocoon extract, the medium-chain fatty acid triglyceride and / or the fat and oil, and the lipophilic emulsifier having a Z or HLB value of 8.5 or less in the cocoon extract-containing composition will be described in detail.
- the lipophilic emulsifier having a medium chain fatty acid triglyceride and / or fat and / or Z or HLB value of 8.5 or less includes MCT alone, fat and oil alone, lipophilic emulsifier alone having an HLB value of 5 or less, MCT and Combination of fats and oils, Combination of MCT and lipophilic emulsifier with HLB value of 5 or less, Combination of fats and oils with lipophilic emulsifier with HLB value of 8.5 or less, MCT and fat with HLB value of 8.5 or less Combined with a lipophilic emulsifier. These combinations can be appropriately selected depending on the content of the Japanese extract.
- the lipophilic emulsifier having an MCT and / or fat and / or HLB value of 8.5 or less is 60% by weight or more. It is.
- MCT alone, fat alone, lipophilic emulsifier alone, combined use of MCT and fat, combined use of MCT and lipophilic emulsifier, combined use of fat and oil with lipophilic emulsifier, combined use of MCT with fat and oil and lipophilic emulsifier Good combination of,
- MCT alone, a lipophilic emulsifier alone, a combination of MCT and a fat or oil, a combination of MCT and a lipophilic emulsifier, a fat or oil MCT alone, a lipophilic emulsifier alone, a combination of MCT and a fat or oil, a combination of MCT and a lipophilic emulsifier, a fat or oil
- the combined amount of MCT, lipophilic emulsifier, and MCT, fat and oil, and lipophilic emulsifier in any combination is more than 50% by weight and less than 60% by weight.
- the weight ratio of fats and fats to lipophilic emulsifiers which is preferably used in combination with MCT or with lipophilic emulsifiers, is 99.9 / 0.1-0.1 / 99.9 is preferred, and more preferably 90/10-0.1 / 99.9. It is preferable to set the weight ratio of the lipophilic emulsifier to be high in order to increase the ratio of fats and oils when the priority is placed on the fluidity and to improve the adhesion.
- the content of the cocoon extract is 50% by weight or more and less than 60% by weight
- MCT alone, a lipophilic emulsifier alone, a combination of MCT and a fat, a combination of MCT and a lipophilic emulsifier, Combinations of fats and lipophilic emulsifiers, combined use of MCTs and fats and lipophilic emulsifiers, in any combination the total amount is more than 40% by weight and not more than 50% by weight. Since fats and oils alone may not sufficiently improve the caking properties, the combination of fats and oils with MCTs or the combination of fats and oils with a lipophilic emulsifier is preferred, and both fluidity and adhesion are greatly improved.
- the weight ratio of the fat and oil to the lipophilic emulsifier is preferably 90Z10 0.1 / 99.9 force S, more preferably 75 / 25-0.1 / 99.9.
- the emulsifier ratio is set in a range higher than the case where the content of the product derived from corn is more than 40 wt% and less than 50 wt%.
- the weight ratio of oil and fat to MCT when using oil and fat together with MCT is preferably 90 / 10-0.1 / 99.9, more preferably 70 / 30-0.1 / 99.9, and even more preferably f.
- the ratio is 50 / 50-0.1 / 99.9, and the MCT ratio is higher and the range is set as compared with the case where the content of konkon extract is more than 0% and less than 50% by weight. It is preferable to set the weight ratio of the lipophilic emulsifier to be higher in order to increase the ratio of fats and oils when the priority is given to the fluidity and to prioritize the improvement in adhesion.
- the weight ratio of MCT to the lipophilic emulsifier is preferably 90/10 to 10/90. Within this range, both fluidity and adhesion are significantly improved.
- the combination use of MCT and a lipophilic emulsifier when the content of the cocoon extract is 60% by weight or more, the combination use of MCT and a lipophilic emulsifier, the combination use of a fat and oil with a lipophilic emulsifier, and the combination use of MCT with a fat and oil and a lipophilic emulsifier are preferred.
- the combined amount of MCT and lipophilic emulsifier is more preferable, and the total amount is less than 40% by weight.
- the weight ratio of the MCT to the lipophilic emulsifier is not particularly limited, but is preferably 0.1 / 99.9 to 99.9 / 0.1, more preferably 10/90. 90/10, more preferably 25 / 75-75 / 25, and most preferably 40 / 60-60 / 40.
- fluidity is prioritized, the ratio of fats and oils is increased to improve adhesion. If priority is given, it is preferable to set the weight ratio of the lipophilic emulsifier to be high.
- the composition of the icon extract is preferably adjusted under heating conditions as needed, and more preferably at about 20-60 ° C.
- a predetermined amount of a cocoon extract and a predetermined amount of fats and oils or Z or a lipophilic emulsifier may be uniformly mixed by stirring under a predetermined temperature heating condition, for example, a paddle mixer.
- Homomixer, A homogenizer, a high-pressure homogenizer, a colloid minole, a bead mill, or the like can be used.
- the composition containing the radish extract prepared by the above-described method is preferably in the form of a capsule for more effective ingestion than the power that can be added to food as it is.
- Soft capsules, hard capsules, seamless capsules and the like can be used.
- various vitamins such as vitamins A, C, D, and E, and a formulation base such as beeswax and the like may be further added to the icon extract composition according to the purpose.
- licorice hydrophobic extract, clove extract, cinnamon extract, etc. which has the effect of preventing or ameliorating multiple 'risk' factor syndrome, or materials commonly used as foods, and food additives such as antioxidants May be added.
- ⁇ Flows out quickly
- ⁇ Flows out slowly
- A Flows out slowly when heated to 40 ° C
- X Almost flows out even when heated to 40 ° C
- * Emulsifier even when stirred Is not uniform and cannot be evaluated in a separated state.
- ⁇ uniform and fine slurry state
- ⁇ uniform but granular slurry state
- ⁇ uniform when stirred, but solid-liquid separation in a short time when allowed to stand
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Obesity (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Nutrition Science (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
Abstract
Description
Claims
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006511991A JPWO2005097152A1 (ja) | 2004-03-31 | 2005-03-23 | 粘結性が改善されたウコン抽出物含有組成物 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004107212 | 2004-03-31 | ||
| JP2004-107212 | 2004-03-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2005097152A1 true WO2005097152A1 (ja) | 2005-10-20 |
Family
ID=35124833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2005/005175 Ceased WO2005097152A1 (ja) | 2004-03-31 | 2005-03-23 | 粘結性が改善されたウコン抽出物含有組成物 |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JPWO2005097152A1 (ja) |
| WO (1) | WO2005097152A1 (ja) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010043032A (ja) * | 2008-08-13 | 2010-02-25 | Fuji Chem Ind Co Ltd | 高濃度アスタキサンチン抽出物 |
| EP2410874A1 (en) * | 2009-03-26 | 2012-02-01 | Abbott Laboratories | Nutritional composition comprising curcuminoids and methods of manufacture |
| JP2013202005A (ja) * | 2012-03-29 | 2013-10-07 | National Agriculture & Food Research Organization | クルクミン類含有油脂およびその製造方法 |
| JP2015527361A (ja) * | 2012-08-21 | 2015-09-17 | カリフォルニア ノースステイト カレッジ オブ ファーマシー, エルエルシーCalifornia Northstate College Of Pharmacy, Llc | ウコン属抽出物のための新規の処方物および使用 |
| CN105056157A (zh) * | 2015-09-22 | 2015-11-18 | 郭新奎 | 一种治疗急性胰腺炎的组合物及其制备方法 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6444583B2 (ja) * | 2013-03-22 | 2018-12-26 | 小林製薬株式会社 | 経口組成物 |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0965864A (ja) * | 1995-08-30 | 1997-03-11 | Riken Vitamin Co Ltd | 食品用酸化防止剤製剤 |
| JPH09143086A (ja) * | 1995-11-22 | 1997-06-03 | San Eng:Kk | 皮膚疾患治療剤及び化粧料 |
| JPH10179086A (ja) * | 1996-11-05 | 1998-07-07 | Riken Vitamin Co Ltd | 植物ステロールを含有する油溶化液及び飲食物並びにその製造方法 |
| JP2001161306A (ja) * | 1999-12-03 | 2001-06-19 | Ezaki Glico Co Ltd | 嗜好性に優れたゼラチンカプセルの製法 |
| WO2002047699A1 (en) * | 2000-12-12 | 2002-06-20 | Kaneka Corporation | Compositions for preventing or ameliorating multiple risk factor syndromes |
| JP2003137799A (ja) * | 2001-03-28 | 2003-05-14 | Kiyotoshi Oshiro | ウコン含有ジアシルグリセロール溶液とその製造方法。 |
| WO2003084556A1 (en) * | 2002-04-04 | 2003-10-16 | Kaneka Corporation | Process for producing fat composition containing hydrophobic components of glycyrrhiza |
-
2005
- 2005-03-23 WO PCT/JP2005/005175 patent/WO2005097152A1/ja not_active Ceased
- 2005-03-23 JP JP2006511991A patent/JPWO2005097152A1/ja not_active Withdrawn
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0965864A (ja) * | 1995-08-30 | 1997-03-11 | Riken Vitamin Co Ltd | 食品用酸化防止剤製剤 |
| JPH09143086A (ja) * | 1995-11-22 | 1997-06-03 | San Eng:Kk | 皮膚疾患治療剤及び化粧料 |
| JPH10179086A (ja) * | 1996-11-05 | 1998-07-07 | Riken Vitamin Co Ltd | 植物ステロールを含有する油溶化液及び飲食物並びにその製造方法 |
| JP2001161306A (ja) * | 1999-12-03 | 2001-06-19 | Ezaki Glico Co Ltd | 嗜好性に優れたゼラチンカプセルの製法 |
| WO2002047699A1 (en) * | 2000-12-12 | 2002-06-20 | Kaneka Corporation | Compositions for preventing or ameliorating multiple risk factor syndromes |
| JP2003137799A (ja) * | 2001-03-28 | 2003-05-14 | Kiyotoshi Oshiro | ウコン含有ジアシルグリセロール溶液とその製造方法。 |
| WO2003084556A1 (en) * | 2002-04-04 | 2003-10-16 | Kaneka Corporation | Process for producing fat composition containing hydrophobic components of glycyrrhiza |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010043032A (ja) * | 2008-08-13 | 2010-02-25 | Fuji Chem Ind Co Ltd | 高濃度アスタキサンチン抽出物 |
| EP2410874A1 (en) * | 2009-03-26 | 2012-02-01 | Abbott Laboratories | Nutritional composition comprising curcuminoids and methods of manufacture |
| JP2012521431A (ja) * | 2009-03-26 | 2012-09-13 | アボット・ラボラトリーズ | クルクミノイドを含む栄養組成物および製造方法 |
| JP2013202005A (ja) * | 2012-03-29 | 2013-10-07 | National Agriculture & Food Research Organization | クルクミン類含有油脂およびその製造方法 |
| JP2015527361A (ja) * | 2012-08-21 | 2015-09-17 | カリフォルニア ノースステイト カレッジ オブ ファーマシー, エルエルシーCalifornia Northstate College Of Pharmacy, Llc | ウコン属抽出物のための新規の処方物および使用 |
| US10231940B2 (en) | 2012-08-21 | 2019-03-19 | California Northstate College Of Pharmacy, Llc | Method of producing a safe, whole-extract of curcuma for oral and topical use |
| US10973778B2 (en) | 2012-08-21 | 2021-04-13 | California Northstate College Of Pharmacy, Llc | Using edible carriers to produce Curcuma extracts for oral and topical use |
| US12053439B2 (en) | 2012-08-21 | 2024-08-06 | California Northstate College Of Pharmacy, Llc | Edible, single-extraction curcuma extracts |
| CN105056157A (zh) * | 2015-09-22 | 2015-11-18 | 郭新奎 | 一种治疗急性胰腺炎的组合物及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2005097152A1 (ja) | 2008-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1309813C (zh) | 油脂组合物 | |
| CN103841833B (zh) | 油脂组合物 | |
| CN104187627B (zh) | 一种降血脂组合物及其在制备具有降血脂功能的保健食品中的应用 | |
| JP7017043B2 (ja) | 粉末油脂、これを含有する飲食品 | |
| JP5421674B2 (ja) | ソフトカプセル用乳化組成物及びソフトカプセル剤 | |
| CN1179026C (zh) | 油脂组合物 | |
| JP2007512407A (ja) | 共役リノール酸のジグリセライドの豊富な油脂組成物 | |
| KR20170083048A (ko) | 분말유지, 당해 분말유지를 포함하는 음식품, 및 당해 분말유지의 제조방법 | |
| JP5033553B2 (ja) | 乳化安定剤 | |
| WO2009034124A1 (en) | Omega-3 stabilisation towards oxidation | |
| CN102918140A (zh) | 处理食用油的方法 | |
| WO2005097152A1 (ja) | 粘結性が改善されたウコン抽出物含有組成物 | |
| JP6694726B2 (ja) | O/d型乳化組成物、水中油型乳化組成物、飲食品及び食品用素材 | |
| CN109475141A (zh) | 油掺合物和其制备方法 | |
| JPS61118318A (ja) | 血清脂質改善用組成物 | |
| Hassim et al. | Characteristics of sunflower wax, carnauba wax and beeswax in palm superolein blended oil | |
| CN103596428B (zh) | 包含极长链ω‑3多不饱和脂肪酸的氧化稳定脂肪 | |
| JP2016104003A (ja) | 酸性分離液状調味料 | |
| JP4268473B2 (ja) | 油脂組成物 | |
| EP3000328B1 (en) | Fat composition | |
| JP6843376B2 (ja) | カプセル皮膜組成物及びカプセル | |
| JPS61118323A (ja) | 血清脂質改善作用を有する組成物 | |
| CN103118546A (zh) | 油脂组合物 | |
| CN1794922A (zh) | 聚甘油脂肪酸酯以及含有其的乳化或增溶化组合物 | |
| CN105247029A (zh) | 油脂组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2006511991 Country of ref document: JP |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
| 122 | Ep: pct application non-entry in european phase |